Patent loophole enables access to costly drug

A family from South Africa traveled to Bangladesh to purchase a cheaper, locally produced generic version of the cystic fibrosis drug Trikafta, which is unaffordable in many countries due to high prices set by the patent-holder, Vertex Pharmaceuticals. The Bangladeshi drug, Triko, costs significantly less and has been approved by Bangladesh's regulatory authority, providing access to life-changing treatment for patients who cannot afford the original. This reverse-engineered medication offers hope to many with cystic fibrosis in developing countries, despite ongoing legal and patent disputes.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل